MOUNTAIN VIEW, Calif., Feb. 20, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, is scheduled to present at three upcoming investor conferences.
- Citi 2013 Global Healthcare Conference, The Hilton New York
-Monday, February 25, 2013 at 9:35 a.m. Eastern Time
- RBC Capital Markets 2013 Healthcare Conference, The New York Palace
-Wednesday, February 27, 2013 at 9:00 a.m. Eastern Time
- Cowen & Company 33rd Annual Health Care Conference, The Boston Marriott Copley Place
-Tuesday, March 5, 2013 at 10:00 a.m. Eastern Time
Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcasts will remain available on the Company's website for fourteen (14) days following each presentation.
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. The Company's most advanced drug candidate, vercirnon (also known as Traficet-EN, CCX282 or GSK1605786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. The Company's lead independent drug candidate, CCX140, a CCR2 inhibitor, has been shown to be safe and well-tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. In addition, CCX872, the Company's next-generation CCR2 inhibitor, is in Phase I clinical development. Other clinical programs include CCX354 (also known as GSK2941266), a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis; CCX168, a C5aR inhibitor in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and CCX507, the Company's wholly-owned de novo CCR9 inhibitor, which is now in Phase I clinical development. ChemoCentryx also has several programs in advanced preclinical development.
CCXI - G
Source: ChemoCentryx, Inc.
CONTACT: ChemoCentryx Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer; or Markus J. Cappel, Ph.D. Chief Business Officer 650-210-2900 firstname.lastname@example.org Media Inquiries: Burns McClellan Justin Jackson 212-213-0006 email@example.com